CD274 and breast cancer: Other approaches include blocking the chemokine receptor CXCR2 to prevent MDSC recruitment into the tumor, which sensitizes a mouse model of rhabdomyosarcoma to anti-PD-1 (66), and using the repurposed drug ibrutinib which inhibits MDSCs and sensitizes murine breast cancer models to anti-PD-L1 (67, 68).